Giugliano, Robert PRobert PGiuglianoRuff, Christian TChristian TRuffBraunwald, EugeneEugeneBraunwaldMurphy, Sabina ASabina AMurphyWiviott, Stephen DStephen DWiviottHalperin, Jonathan LJonathan LHalperinWaldo, Albert LAlbert LWaldoEzekowitz, Michael DMichael DEzekowitzWeitz, Jeffrey IJeffrey IWeitzŠpinar, JindřichJindřichŠpinarRuzyllo, WitoldWitoldRuzylloRuda, MikhailMikhailRudaKoretsune, YukihiroYukihiroKoretsuneBetcher, JoshuaJoshuaBetcherShi, MinggaoMinggaoShiGrip, Laura TLaura TGripPatel, Shirali PShirali PPatelPatel, IndravadanIndravadanPatelHanyok, James JJames JHanyokMercuri, MicheleMicheleMercuriAntman, Elliott MElliott MAntmanFU-TIEN CHIANG2021-03-112021-03-112013-11-280028-4793https://scholars.lib.ntu.edu.tw/handle/123456789/551886Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.animationFACTOR XA INHIBITOR; ORAL ANTICOAGULANTS; STROKE; PHARMACOKINETICS; METAANALYSIS; GENERATION; PREVENTION; SAFETYjournal article10.1056/NEJMoa1310907242513592-s2.0-84888362796WOS:000327467500007https://api.elsevier.com/content/abstract/scopus_id/84888362796